Will the potential of peroxisome proliferator-activated receptor agonists be realized in the clinical setting?
Drugs targeting both peroxisome proliferator-activated receptor-gamma (PPAR-gamma) agonists (the thiazolidinediones) and PPAR-alpha (the fibrates) have already been developed for clinical use. However, the thiazolidinediones, currently prescribed to treat hyperglycemia and improve peripheral insulin resistance, may also have cardiovascular benefits that have yet to be fully realized. Animal models of atherosclerosis have shown that the thiazolidinediones reduce the extent of atherosclerotic lesions and inhibit macrophage accumulation. Clinical studies have also shown that these drugs improve the lipid profile of patients at risk of developing atherosclerosis and reduce circulating levels of inflammatory markers. This combination of lower lipid concentrations and reduced inflammation may explain the cardiovascular benefits of this class of drugs. Early trials in patients with coronary stents have reported promising findings, with restenosis rates being greatly reduced with thiazolidinedione therapy. It is hoped that the results of future clinical trials will continue to be encouraging, so that the thiazolidinediones' cardiovascular benefits can be fully realized in the clinic.
Department of Medicine/Cardiology, German Heart Institute, Berlin, Germany.
Florian
F
Blaschke
Dennis
D
Bruemmer
Ronald E
RE
Law
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D001161:Arteriosclerosis / Q000188:drug therapy* / Q000276:immunology / Q000517:prevention & control; D023903:Coronary Restenosis / Q000276:immunology / Q000517:prevention & control; D005947:Glucose / Q000378:metabolism; D006801:Humans; D007249:Inflammation / Q000188:drug therapy / Q000276:immunology; D050356:Lipid Metabolism; D018160:Receptors, Cytoplasmic and Nuclear / Q000819:agonists / Q000276:immunology / Q000627:therapeutic use*; D014157:Transcription Factors / Q000819:agonists / Q000276:immunology / Q000627:therapeutic use*
D000894:Anti-Inflammatory Agents, Non-Steroidal; D018160:Receptors, Cytoplasmic and Nuclear; D014157:Transcription Factors; D005947:Glucose